Facebook Twitter

This CEO says COVID-19 developer will know if vaccine works by end of October

Albert Bourla, the head of pharmaceutical giant Pfizer, talked to “Face the Nation” about the vaccine.

SHARE This CEO says COVID-19 developer will know if vaccine works by end of October
In this May 4, 2020 photo provided by the University of Maryland School of Medicine, the first patient enrolled in Pfizer’s COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore, receives an injection.

In this May 4, 2020, photo provided by the University of Maryland School of Medicine, the first patient enrolled in Pfizer’s COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore, receives an injection.

University of Maryland School of Medicine via Associated Press

Albert Bourla, the head of pharmaceutical giant Pfizer, recently said in an interview with “Face the Nation” that there’s a pretty “good chance” the company will know if the coronavirus vaccine works by the end of October.

What’s going on:

Bourla told “Face the Nation”that it’s still unknown if Americans will have a chance to get the vaccine before the end of the year due to distribution concerns.

  • So far, studies suggest to Pfzier that “we have a good chance that we will know if the product works by the end of October,” Bourla told“Face the Nation.”

The company still plans to produce to vaccine at the end of the year, believing the government will offer approval.

  • “We started already manufacturing and we have already manufactured hundreds of thousands of doses, so just in case we have a good study readout, conclusive and FDA, plus the advisory committee feels comfortable that we will be ready.”

Next steps

Pfizer sent a proposal to the Food and Drug Administration on Saturday to expand its recent trial to include 44,000 more participants, CNBC reports. The company originally sought out 30,000 people or the trial.

  • Pfizer and BioNTech’s vaccine is one of the 35 potential COVID-19 vaccines currently in development across the world and in testing, the New York Postreports.